urnal/CategoryOfJournal.aspx?CategoryID=7"> Medicine & Healthcare
Totsuka, M., Miyashita, Y., Itoh, Y., Hashiguchi, S., Urano, Y., Watanabe, J., Tomioka, H. and Shirai, K. (1997) Properties of Fast Beta Lipoprotein on the PAG Disc Electrophoresis and Its Role in Diabetic Complications. Journal of the Japan Diabetes Society, 40, 503-511. (In Japanese) https://www.jstage.jst.go.jp/article/tonyobyo1958/40/8/40_8_503/_pdf
JOURNAL NAME: Open Journal of Molecular and Integrative Physiology, Vol.7 No.1, February 28, 2017
ABSTRACT: Aims: There has been no evidence on the effects of evolocumab, protein convertase subtilisin/kexin type 9 (PCSK9) inhibitor, on small size LDL. We observationally investigated the efficacy and side effects of evolocumab on the LDL subfraction particle diameter using PAGE system for lipoprotein analysis. Methods: We defined 30 patients with high-risk hyperlipidemia. As for analysis of LDL subfraction profile, we used polyacrylamide gel electrophoresis three methods: 1) 3% nondenatured poly-acrylamide gel electrophoresis method (3%PAGE), 2) 2% - 16% nondenatured poly-acrylamide gradient gel electro-phoresis method (2% - 16% GGE) and 3) 2.7% - 5% GGE. Evolocumab 140 mg/day administered together with statin significantly improved serum total cholesterol (TC), triglyceride (TG), high-dense lipoprotein-cholesterol (HDL-C), and LDL-C after four-week treatment. Results: TC, TG, HDL-C and LDL-C levels were improved by, respectively, 33%, 20%, 10%, and 54%. The mean LDL size significantly increased from 25.6 ± 0.4 nm to 26.4 ± 0.8 nm. The small dense LDL-cholesterol (sdLDL-C), large buoyant LDL-cholesterol (lbLDL-C), and mid-band lipoprotein-cholesterol were reduced, respectively. Therefore, the preliminary study on this paper can be the first step into a new insight on the world of lipid metabolism. Conclusion: Short-term administration of evolocumab addedons to statin therapy, significantly reduced small size LDL levels.